8-K current report · filed Oct 13, 2026

BridgeBio Pharma, Inc. (BBIO) 8-K Current Report: October 13, 2026

Item 8.01Item EX-99.1BBIO overview

Short answer

BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on October 13, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA accepted BridgeBio’s NDA for oral infigratinib in children with achondroplasia.

BridgeBio Pharma, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • FDA accepted BridgeBio’s NDA for oral infigratinib in children with achondroplasia
  • Priority review accelerates FDA evaluation and may shorten the path to potential approval
  • Regulatory progress could strengthen BridgeBio’s pediatric achondroplasia franchise and commercial outlook
  • Full development and review details appear in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • FDA accepted oral infigratinib NDA with Priority Review, setting a February 4, 2027 PDUFA target date
  • Potential first approved oral achondroplasia therapy, supporting BridgeBio’s planned U.S. launch upon approval
  • PROPEL 3 achieved +2.10 cm/year AHV treatment effect versus placebo, p<0.0001
  • Statistically significant improvements in body proportionality and arm span, strengthening differentiation beyond height
  • Planned EMA marketing application in fourth quarter 2026 expands potential international commercialization path

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other BridgeBio Pharma, Inc. 8-K filings

Get the next BBIO 8-K as it lands

Follow BBIO for push alerts, or ask the research agent what this filing means.